{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:00:07Z","timestamp":1785272407171,"version":"3.55.0"},"reference-count":36,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnumed.125.270444","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:25:12Z","timestamp":1759519512000},"page":"1956-1963","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing [\n                    <sup>212<\/sup>\n                    Pb]Pb-AB001 Radiopharmaceutical Therapy Schedules in PSMA-Positive Subcutaneous Prostate Cancer Xenografts"],"prefix":"10.2967","volume":"66","author":[{"given":"Anna Julie Kjl","family":"Hyvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilde Yuli","family":"Stenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugile","family":"Liukaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Repetto-Llamazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Wangen-Riise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wiig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"Juzeniene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"2026030506250583000_66.12.1956.1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.euf.2024.07.016","article-title":"New drugs for targeted radionuclide therapy in metastatic prostate cancer","volume":"10","author":"Hbert","year":"2024","journal-title":"Eur Urol Focus."},{"key":"2026030506250583000_66.12.1956.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026030506250583000_66.12.1956.3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur Urol."},{"key":"2026030506250583000_66.12.1956.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2026030506250583000_66.12.1956.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268457"},{"key":"2026030506250583000_66.12.1956.6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/atm-23-1842","article-title":"Design of 225Ac-PSMA for targeted alpha therapy in prostate cancer","volume":"12","author":"Kairemo","year":"2024","journal-title":"Ann Transl Med."},{"key":"2026030506250583000_66.12.1956.7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026030506250583000_66.12.1956.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395"},{"key":"2026030506250583000_66.12.1956.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266774"},{"key":"2026030506250583000_66.12.1956.10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40658-022-00481-z","article-title":"Quantitative SPECT\/CT imaging of lead-212: a phantom study","volume":"9","author":"Kvassheim","year":"2022","journal-title":"EJNMMI Phys."},{"key":"2026030506250583000_66.12.1956.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269299"},{"key":"2026030506250583000_66.12.1956.12","unstructured":"Hall EJ Giaccia AJ . Radiobiology for the Radiologist. 8th ed. Lippincott Williams & Wilkins; 2018."},{"key":"2026030506250583000_66.12.1956.13","doi-asserted-by":"crossref","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"2026030506250583000_66.12.1956.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262069"},{"key":"2026030506250583000_66.12.1956.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023"},{"key":"2026030506250583000_66.12.1956.16","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer."},{"key":"2026030506250583000_66.12.1956.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256388"},{"key":"2026030506250583000_66.12.1956.18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1103"},{"key":"2026030506250583000_66.12.1956.19","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cancers14112784","article-title":"Factors influencing the therapeutic efficacy of the PSMA targeting radioligand 212Pb-NG001","volume":"14","author":"Stenberg","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2026030506250583000_66.12.1956.20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-023-06494-9","article-title":"Structural modifications toward improved lead-203\/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors","volume":"51","author":"Lee","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026030506250583000_66.12.1956.21","first-page":"175","article-title":"Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs","volume":"7","author":"Goel","year":"2001","journal-title":"Clin Cancer Res."},{"key":"2026030506250583000_66.12.1956.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.160"},{"key":"2026030506250583000_66.12.1956.23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026030506250583000_66.12.1956.24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/pharmaceutics14040731","article-title":"Hematological toxicity in mice after high activity injections of 177Lu-PSMA-617","volume":"14","author":"Kristiansson","year":"2022","journal-title":"Pharmaceutics."},{"issue":"2","key":"2026030506250583000_66.12.1956.25","first-page":"242076","article-title":"68Ga-PSMA receptor saturation during radioligand therapy: assessment using a PBPK model [abstract]","volume":"65","author":"Costa","year":"2024","journal-title":"J Nucl Med."},{"key":"2026030506250583000_66.12.1956.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1485"},{"key":"2026030506250583000_66.12.1956.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"},{"key":"2026030506250583000_66.12.1956.28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","article-title":"Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression?","volume":"12","author":"Kind","year":"2022","journal-title":"EJNMMI Res."},{"key":"2026030506250583000_66.12.1956.29","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.3390\/ijms22094815","article-title":"Evaluation of the PSMA-binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer","volume":"22","author":"Stenberg","year":"2021","journal-title":"Int J Mol Sci."},{"key":"2026030506250583000_66.12.1956.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264009"},{"key":"2026030506250583000_66.12.1956.31","doi-asserted-by":"crossref","unstructured":"Hyvik AJK Kvassheim M Ma L-W . Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. Eur J Nucl Med Mol Imaging. May 21, 2025 [Epub ahead of print].","DOI":"10.1007\/s00259-025-07330-y"},{"key":"2026030506250583000_66.12.1956.32","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026030506250583000_66.12.1956.33","doi-asserted-by":"publisher","DOI":"10.3109\/09553002.2011.538127"},{"key":"2026030506250583000_66.12.1956.34","unstructured":"PSMA and beyond 2025: 212Pb-PSMA vs 225Ac-PSMAfrom biology to supply. UroToday website. https:\/\/www.urotoday.com\/conference-highlights\/2025-ucsf-ucla-psma-conference\/159340-psma-and-beyond-2025-212pb-psma-vs-225Ac-psma-from-biology-to-supply.html. Accessed September 16, 2025."},{"key":"2026030506250583000_66.12.1956.35","doi-asserted-by":"publisher","DOI":"10.1080\/095530099139746"},{"key":"2026030506250583000_66.12.1956.36","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0671"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:19:03Z","timestamp":1785269943000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,3]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnumed.125.270444"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270444","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}